文献速递自身炎症与 IgG4 相关病

卡那奴单抗治疗成人斯蒂尔病的疗效与安全性:系统综述

Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2021-08-27

结果显示68.7%患者达到完全缓解,16.2%部分改善,15.1%无改善或排除;69例报告210次不良事件,以呼吸道感染等常见,严重不良事件包括巨噬细胞活化综合征和严重感染。结论认为需更多高质量研究支持其疗效,但安全性可接受。

要点

  • 卡那奴单抗在AOSD中完全缓解率68.7%,部分改善16.2%。
  • 常见不良事件为呼吸道感染、关节痛、疾病复发等。
  • 严重不良事件包括巨噬细胞活化综合征和严重感染。

核心结论

  • 卡那奴单抗治疗AOSD显示较好疗效和可接受的安全性,但需更多高质量研究证实。

研究设计与样本

  • 遵循PRISMA指南检索Scopus、Web of Science、PubMed和Cochrane Library截至2021年3月的文献,纳入随机对照试验、汇总分析、观察性研究、病例系列和病例报告。

主要发现

  • 共99例患者中,68.7%在观察期末达到全身和关节炎表现的完全缓解,16.2%部分改善,15.1%无临床改善或被排除。
  • 69例患者报告210次不良事件,多数为呼吸道感染、关节痛、疾病复发、腹痛、恶心和腹泻。
  • 最常见严重不良事件包括巨噬细胞活化综合征和严重感染。
  • 较大比例患者观察到减少糖皮质激素用量的效应。

临床怎么用

  • 卡那奴单抗可用于AOSD治疗,尤其传统治疗难治者,但需监测感染和巨噬细胞活化综合征等严重不良事件。

局限性

  • 多数纳入研究为病例系列或病例报告,证据等级有限,需设计良好的终点明确的研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adult-onset Still's disease (AOSD) is a rare inflammatory disease, typically characterized by spiking fever, skin rash, and arthralgia or arthritis. Its conventional treatment includes NSAIDs and corticosteroids, and DMARDs as second-line therapy. Frequently, IL-1 inhibitors are also required, mainly in patients refractory to traditional therapy. Canakinumab is a monoclonal antibody that binds IL-1β with high affinity and specificity, making it appropriate for therapeutic purposes in AOSD. OBJECTIVE: The aim of this systematic review was to identify and compile the current data on the efficacy and safety of canakinumab in the treatment of AOSD. METHODS: Following the guidelines established by the PRISMA statement, we searched Scopus, Web of Science, Pubmed, and Cochrane Library for relevant literature up to March 2021. The inclusion criteria comprised: randomized controlled trials, pooled analyses, observational studies, case series, and case reports. RESULTS: Seventeen studies published from 2012 to 2021 were evaluated; 11 of these correspond to case series or case reports, four observational studies, one placebo-controlled phase II trial, and one analysis of pooled systemic juvenile idiopathic arthritis data. In general, out of a total of 99 patients, 68.7% of these presented a complete remission of the systemic and arthritic manifestations at the end of the observation period, while 16.2% of the patients showed a partial improvement of the symptoms and the remaining (15.1%) did not show clinical improvement or were excluded. Moreover, 210 adverse events were reported in 69 patients during canakinumab treatment, of which the majority correspond to respiratory tract infections, arthralgia, disease flares, abdominal pain, nausea, and diarrhea, whereas the most common severe adverse events included macrophage activation syndrome and serious infections. Also, a corticosteroid-sparing effect was observed in a large percentage of patients. CONCLUSION: More studies with solid evidence are needed to support the efficacy of canakinumab in AOSD, although its use is encouraged by the increasing favorable results reported and the efficacy of other IL-1 inhibitors. It was also associated with an acceptable safety profile, similar to expected in IL-1 inhibitor therapy. However, future studies with well-defined endpoints are warranted to examine further the usefulness of canakinumab in AOSD.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Cota-Arce JM, Cota J, De León-Nava MA, et al. Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review. Semin Arthritis Rheum. 2021. PMID: 34493394. doi:10.1016/j.semarthrit.2021.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。